Who is currently selling pertuzumab in Canada?
The only approved pertuzumab product in Canada is Perjeta, a Roche‑manufactured monoclonal antibody used with trastuzumab for HER‑2‑positive breast cancer. It is licensed by Health Canada and available through the national drug formularies and provincial drug plans. No biosimilar has yet received approval.
When can we expect a pertuzumab biosimilar in Canada?
Health Canada adopts the same rigorous review process as the FDA for biosimilars, requiring demonstration of similarity in quality, safety, and efficacy. As of 2026, no Canadian dossier for a pertuzumab biosimilar has been filed, and the first approval in the U.S. is still several years away. Market entry will likely follow the U.S. launch, which is projected for the late 2020s, depending on the applicant’s regulatory strategy.
What is the patent situation for pertuzumab in Canada?
Roche holds multiple patents covering the pertuzumab antibody sequence, manufacturing methods, and use in cancer therapy. The primary Canadian patents, filed in 2007, expire in 2026–2027, giving Roche an exclusive period before generic competition could arise. The PatentWatch database lists the key claims and expiry dates: [1]
Can Canadian clinicians use off‑label alternatives while a biosimilar waits?
No other HER‑2‑blocking monoclonal antibody has the same dual HER‑2 and HER‑3 blockade as pertuzumab. Off‑label use of other agents such as trastuzumab deruxtecan (Enhertu) is possible but involves different mechanisms, dosing schedules, and regulatory status. Physicians must weigh the evidence for efficacy and safety in the specific patient population.
What does Health Canada say about switching to a future pertuzumab biosimilar?
The agency has issued guidance on interchangeability that requires an approved biosimilar to be deemed interchangeable by the regulator. Switching would need a Health‑Canada endorsement, and clinicians should monitor for immunogenicity or loss of efficacy after transition.
How would a pertuzumab biosimilar affect pricing?
Biosimilar entry typically lowers drug costs by 15–30 % in markets that allow substitution. However, Canadian reimbursement models—often tied to negotiated price and therapeutic value—may moderate the price drop. Early negotiations with provincial drug plans will determine actual savings for patients and payers.
What clinical data will a biosimilar need to match?
A biosimilar dossier must include comparative pharmacokinetics, immunogenicity, and at least one pivotal efficacy study in the same indication (HER‑2‑positive metastatic breast cancer). The data must demonstrate no clinically meaningful differences from Perjeta. Post‑approval pharmacovigilance will continue to confirm long‑term safety.
Which companies are pursuing pertuzumab biosimilars?
Several global biopharmaceutical firms have announced plans to develop pertuzumab biosimilars, but none have submitted a Canadian filing as of 2026. The U.S. market is the primary target; companies like Celltrion and Samsung Biologics are active in other antibody biosimilars and may consider pertuzumab later.
What competitive threats exist for the originator?
Other HER‑2 targeted therapies—such as trastuzumab emtansine (Kadcyla) and trastuzumab deruxtecan—continue to gain approvals for different lines of therapy. If a pertuzumab biosimilar enters, Roche will need to maintain the combined dual‑blockade advantage in marketing and reimbursement negotiations.
Where can clinicians find updates on biosimilar approvals?
Health Canada publishes drug approval announcements on its website, and the Canadian Drug Information Portal lists newly approved biologics. Industry watch sites like DrugPatentWatch.com track patent expirations and filing activities, which can signal forthcoming biosimilar development: [2]
---
Sources
[1] DrugPatentWatch. Pertuzumab patents in Canada. https://drugpatentwatch.com/patents/pertuzumab
[2] DrugPatentWatch. Pertuzumab biosimilar development. https://drugpatentwatch.com/biosimilars/pertuzumab